Leading Companies

Halozyme Switzerland GmbH

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies.

Halozyme Switzerland GmbH

Gubelstrasse 22
6300 Zug

Life Science
Bio Technology (Biotech)
Central Functions
Country of Origin

Premium Partner

Partner strategici

Partner istituzionale

Programma ufficiale